Therapy of breast cancer with molecular targeting agents

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Gasparini, Giampietro ^a   Longo, R ^a   Torino, F ^a   Morabito, A ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Breast cancer; Targeted therapy

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EXEMESTANE; GEFITINIB; INTERLEUKIN 12; ISOFLAVONE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; ROFECOXIB; TAMOXIFEN; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VALDECOXIB; VITRONECTIN RECEPTOR;

ALOPECIA; ANEMIA; ANGIOGENESIS; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER TISSUE; CARCINOGENESIS; CARDIOTOXICITY; CELL TRANSFORMATION; CLINICAL STUDY; CLINICAL TRIAL; CONJUNCTIVITIS; CYTOPENIA; DIARRHEA; DRUG APPROVAL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TARGETING; DYSPNEA; EPISTAXIS; FATIGUE; GENETIC ANALYSIS; HUMAN; HYPERTENSION; LETHARGY; MOLECULAR BIOLOGY; MYALGIA; NEUROPATHY; NEUTROPENIA; ONYCHOLYSIS; OPTIMAL DRUG DOSE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; PACLITAXEL; PRENYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; TAXOIDS; VINBLASTINE;

EID: 30644470953     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi905     Document Type: Article

References (75)

1. Salomon DS, Brandt R, Fortunato C, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Rev Oncol Hematol 1995; 19: 183-232.
2. Hill CS, Treisman R. Transcriptional regulation by extracellular signals; mechanisms and specificity. Cell 1995; 80: 199-211.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
4. Querrel N, Wafflart J, Borrichon F et al. The prognostic value of c-erbB2 in primary breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 1995; 35: 283-291.
5. Pegram MD, Finn RS, Arzoo K et al. The effect of her-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547.
6. Carlomagno C, Perrone F, Gallo C et al. c-ErbB2 overexpression decreases the benefit of adjuvant tamoxifen in early breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-2708.
7. McKeage K, Perry CM. Trastuzumab. Drugs 2002; 62: 209-243.
8. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
9. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
10. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
11. Osoba D, Slamon DJ, Burhmore M et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-3113.
12. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
13. Seidman AD, Fornier MN, Esteva FJ et al. Weekly Trastuzumab and paclitaxel for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-2595.
14. Gori S, Colozza M, Mosconi AM et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004; 90: 36-40.
15. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12: 1545-1551.
16. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800-1808.
17. Tedesco KL, Thor AD, Johnson DH et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A Multi-Institutional phase II trial. J Clin Oncol 2004; 22: 1071-1077.
18. Extra JM, Cognetti F, Chan S et al. Randomized phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. ECCO 2003; (Abstr 672).
19. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
20. Jahanzeb M, Mortimer JE, Yunus F et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. The Oncologist 2002; 7: 410-417.
21. Burnstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-2895.
22. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96: 759-769.
23. Burris H III, Yardley DA, Jones S et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatino as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22: 1621-1629.
24. Robert N, Leyland-Jones B, Asmar L et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76: S37
25. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241-2251.
26. Gasparini G, Crivellari D, Filippelli G et al. Weekly paclitaxel (PTC) +trastuzumab (T) as first-line therapy of patients (PTS) with HER-2/neu positive metastatic breast cancer (MBC): A multicenter randomized phase II trial. Ann Oncol 2004; 15
27. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (w) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every three week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004; 23 (Abstr 512).
28. Morabito A, Carillio G, Bonginelli P et al. Trastuzumab in combination with gemcitabine and vinorelbine (T-GEM-VIN) as second- or third-line therapy for HER-2/neu overexpressing metastatic breast cancer (MBC). Ann Oncol 2004; 15 (Abstr A45).
29. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754.
30. Woodburn JR, Barker AJ, Gibson KH et al. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Amer Assoc Cancer Res 1997; 38: 633-634.
31. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
32. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002; 20: 2240-2250.
33. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
34. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-2158.
35. Baselga J, Albanell J, Ruitz A et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22 (Abstr. 24).
36. Robertson JFR, Gutteridge E, Cheung KL et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and (ER)-negative breast cancer: Results from a phase II study. Proc Am Soc Clin Oncol 2003; 22 (Abstr 23).
37. Von Minckwitz G, Jonat W, Fasching P et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Br Cancer Res Treat 2005; 89: 165-172.
38. Fountzilas G, Pectasides D, Skarlos DV et al. Paclitaxel, carboplatin and gefitinib (Iressa, ZD1839) as first-line chemotherapy in patients with advanced breast cancer: A phase II study. San Antonio Breast Cancer Symposium 2003; 82 (Abstr 375).
39. Ciardiello F, Troiani T, Caputo F et al. A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2004; 23 (Abstr 725).
40. Magnani E, Sarmiento R, Fanelli M et al. ZD1839 combined with weekly epidoxorubicin (E) as second-line therapy of advanced breast cancer (ABC): Results of a dose finding study. Proc Am Soc Clin Oncol 2003; 22 (Abstr 177).
41. Lynch TJ, Bell DW, Sardella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smal-cell lung cancer to gefinitib. N Engl J Med 2004; 360: 1219-1239.
42. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefinitib therapy. Science 2004; 304: 1497-1500.
43. Tan AR, Yang X, Hewitt SM et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22: 3080-3090.
44. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
45. Kim KJ, Li B, Winer J, Armanini M et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
46. Gasparini G. Prognostic value of vascular endothelial growth factor (VEGF) in breast cancer. The Oncologist 2000; 5 (Suppl 1): 37-44.
47. Fox SB, Gasparini G, Harris AL. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-289.
48. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-5414.
49. Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. The Oncologist 2004; 9 (Suppl 1): 43-49.
50. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of Capecitabine compared with Bevacizumab plus Capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
51. Morabito A, Carillio G, Longo R, Gasparini G. Thalidomide is inactive in heavily pretreated metastatic breast cancer, Cancer J (in press)
52. Moses MA, Harper J, Fernández CA. A Role for Antiangiogenic therapy in breast cancer. Current Oncology Reports 2004; 6: 42-48.
53. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004; 31 (Suppl 7): 22-29.
54. Gasparini G, Longo R, Sarmiento R, Morabito A. COX-2 inhibitors (Coxibs): A new class of anticancer agents? Lancet Oncol 2003; 4: 605-615.
55. Dannenberg AJ, Howe LR. The role of COX-2 in breast and cervical cancer. Prog Exp Tumor Res 2003; 37: 90-106.
56. Khuder SA, Mutgi AB. Breast cancer and NSAID use: A meta-analysis. Br J Cancer 2001; 84: 1188-1192.
57. Dang CT, Dickler MN, Moasser MM et al. Celecoxib ©and trastuzumab (herceptin) (H) is feasible after H for HER-2/neu overexpressing (H2+) metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol 2003; 21
58. Canney PA. A phase II study of the efficacy and tolerability of the combination of exemestane with the cylooxigenase-2 inhibitor celecoxib in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2000; 22 (Abstr 158).
59. Chow LW, Toi M, Takebayashi Y et al. Neoadjuvant celecoxib and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) for the treatment of locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 2003; 22 (Abstr 327).
60. Toi M, Chow LW et al. Celecoxib anti-aromatase neoadjuvant (CAAN) therapy for locally advanced breast cancer: Preliminary results of a prospective randomized trial. Proc Am Soc Clin Oncol 2003; 22 (Abstr 331).
61. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
62. Solomon S, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
63. Nussmeir NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-1091.
64. Rowinski EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631-3652.
65. Johnston SRD. Farnesyl transferase inhibitors: A novel targeted therapy for cancer. Lancet Oncol 2001; 2: 18-26.
66. Cox AD, Der CJ. Farnasyltransferase inhibitors and cancer treatment: targeting simply ras? Biochem Biophys Acta 1997; 1333: F51-F71.
67. James GL, Golstein JL, Pathak RK et al. PxF, a prenylated protein of perioxsomes. J Biol Chem 1994; 269: 14182-14190.
68. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989; 264: 20422-20429.
69. Jiang K, Coppola D, Crespo NC et al. The phosphoinositide 3-OH kinase/ AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139-148.
70. Liu A, Du W, Liu JP et al. RhoB alteration is necessary for apoptotic and antineoplastic response to farnesyltransferase inhibitors. Mol Cell Biol 2000; 20: 6105-6113.
71. Moasser MM, Sepp-lorenzino L, Khol Ne et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369-1374.
72. Shi B, Yaremko B, hajian G et al. The farnesyl protein transferase SCH66336 synergises with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000; 46: 387-393.
73. Head J, Johnston SRD. Farnesyltransferase inhibitors. Breast Cancer Res 2004; 6: 262-268.
74. Johnston SRD, Hickish T, Ellis PA et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyltransferase inhibitor R115777 (Zarnestra) in patients with advanced breast cancer. J Clin Oncol 2003; 21: 2492-2499.
75. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenger and open questions. J Clin Oncol 2005; 23: 1295-1311.